Genitourinary Drugs: Technologies and Global Markets
The total market for genitourinary drugs is projected to increase from $26.5 billion in 2011 to $30.7 billion in 2016 at a compound annual growth rate (CAGR) of 3% for a period of five years, from 2011 to 2016.
SCOPE OF REPORT
Current and projected product forecasts during the forecast period (2011 to 2016) are discussed. New product launches will be discussed. Revenue figures for 2010 are in an actual figure, except where actual results have not been reported due to the release timing of the report.
The report includes analysis of leading and emerging drug products for each genitourinary disease. Profiles of manufacturers of leading products and their specific products are provided. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products will alter the quality of life of patients with genitourinary diseases.
Market figures are based on revenues at the manufacturers’ level and are projected at 2011-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, for new product introductions, expanded markets for existing products, and other factors affecting the market
Included in this report are forecasts by product, product category and company from 2009 through 2016. The study is arranged to offer an overview of the genitourinary disease drug market accompanied by product, company, geography and mechanism of action, with forecasts broken down and covered by geographic region or country. Virtually the entire globe is covered to include prevalence data for each drug subsegment.
Where possible, epidemiological data is presented to underscore the importance of these diseases in the world population and the potential morbidity/mortality resulting from ineffective treatment of these diseases worldwide. Patent and clinical trial information is reviewed for various drugs. The status of approvals of drugs in each disease segment by the FDA and regulatory agencies in other countries is reviewed.
Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.
Diagnostics for each disease area and various drugs are described. However, diagnostics are not included in market figures, as they are outside of the scope of this report.
All market share data presented is on a global basis, unless specifically noted.
Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy, where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development. Jackson Highsmith is a pseudonym of the author.